Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394093 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL14148977 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL2972573 | 0.83 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL395429 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| Hydrochloric Acid SCHEMBL14108563 | 0.82 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL3399492 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL6843353 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL25991 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL31252092 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL4688024 | 0.78 | DDB1 (0.46) | ALDH1A1MAPK1L3MBTL1HCAR2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497287-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2231589-B1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8314128-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2231589-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076399-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885MAPK1 1046/4885L3MBTL1 2249/4885 |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885MAPK1 1046/4885L3MBTL1 2249/4885 |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885MAPK1 1046/4885L3MBTL1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.